Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q1 2026 › vs Q4 2025
Ginkgo Bioworks Holdings (DNA) Q1 2026 vs Q4 2025 (quarter over quarter)
Ginkgo Bioworks Holdings's revenue fell $13.9M (-42%) from $33.4M in Q4 2025 to $19.5M in Q1 2026.
Ginkgo Bioworks Holdings, Q1 2026: revenue $19.5M (-49% year over year), operating margin -366.5%, net loss $82.6M, operating cash flow −$46.7M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.5M | $33.4M | −$13.9M | -42% |
| Income tax benefit | $80K | $643K | −$563K | -88% |
| Net loss | $82.6M | $80.8M | $1.8M | +2% |
| Costs & expenses | $102M | $115M | −$12.6M | -11% |
| Operating costs | $90.8M | $104M | −$13.3M | -13% |
| Interest & other, net | $11.3M | $10.6M | $651K | +6% |
| Research & development | $49.9M | $50.1M | −$207K | -0.4% |
| General & admin | $37.8M | $46.0M | −$8.2M | -18% |
| Operating cash sources | $82.6M | $80.8M | $1.8M | +2% |
| Depreciation & amortization | $12.8M | $13.7M | −$864K | -6% |
| Share-based compensation | $15.9M | $21.0M | −$5.2M | -25% |
| Working capital & other | $7.2M | −$1.6M | $8.9M | — |
| Cash used in operations | $46.7M | $47.7M | −$992K | -2% |
| Net loss absorbed | $82.6M | $80.8M | $1.8M | +2% |
Questions
How much did Ginkgo Bioworks Holdings's revenue grow quarter over quarter in Q1 2026?
Ginkgo Bioworks Holdings's revenue fell $13.9M (-42%) from $33.4M in Q4 2025 to $19.5M in Q1 2026.